🎗️ Проект автоматически собирает и публикует онкологические новости из проверенных медицинских источников — 24/7, со ссылкой на первоисточник
Английские новости переводятся автоматически
Онкология

Combining targeted therapies significantly boosted survival in kidney cancer study

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer. Saby George, M.D., FACP…